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Abstract 
The aim of this review was to determine the magnitude of the placebo and nocebo effect on sport 
performance. Articles published before March 2019 were located using Medline, Web of Science, 
PubMed, EBSCO, Science Direct, and Scopus. Studies that examined placebo and nocebo effects of an 
objective dependent variable on sports performance, which included a control or baseline condition, 
were included in the analysis. Studies were classified into two categories of ergogenic aids: 1) 
nutritional and 2) mechanical. Cohen’s d effect sizes were calculated from 32 studies involving 1,513 
participants. Small to moderate placebo effects were found for both placebo (d = 0.36) and nocebo (d 
= 0.37) effects and when separated by nutritional (d = 0.35) and mechanical (d = 0.47) ergogenic aids. 
The pooled effect size revealed a small to moderate effect size across all studies (d = 0.38). Results 
suggest that placebo and nocebo effects can exert a small to moderate effect on sports performance.  
 
Key Words: belief, effectiveness, motor, nocebo, nutrition, supplements 
 
 
  
3 
 
Introduction 
The placebo effect is a psychobiological response to a purported beneficial treatment (Hurst, Foad, 
Coleman, & Beedie, 2017). The nocebo effect is the opposite, a psychobiological response to a 
purported harmful treatment (Beedie et al., 2018). In the last two decades, research in sport and 
exercise science suggests that placebo and nocebo effects can significantly influence sport 
performance (Beedie et al., 2018). In this review, we aim to determine the magnitude of the placebo 
and nocebo effect on sport performance in studies published to date.  
 
Historically, placebos are used as a control treatment that is theoretically indistinguishable from the 
experimental treatment, but without the essential biological or mechanical active component. The 
‘true’ treatment effect is reported as the difference between the effect of the experimental 
drug/substance/method compared to the effect of the placebo, while the magnitude of placebo 
effects is the difference between the effect of the placebo and any change in performance in a 
control group given no treatment. However, the magnitude of the placebo effect can be 
misattributed to other phenomena, such as response biases, regression to the mean and natural 
history of the condition under investigation. It is therefore important that any estimate of the 
magnitude of the placebo and nocebo effect is interpreted in carefully designed investigations in 
which a placebo is compared with a natural history control group or baseline condition (i.e. where 
participants receive no treatment of any kind).  
 
To the authors’ knowledge, there have only been two reviews investigating placebo effects on sport 
performance (Beedie & Foad, 2009; Bérdi, Köteles, Szabó, & Bárdos, 2011). While both papers report 
the significant influence placebo effects have on performance in sport, these reviews focus only on 
nutritional ergogenic aids (e.g. caffeine, carbohydrate and sodium bicarbonate). This arguably limits 
our understanding of the full range and magnitude of placebo and nocebo effects in sports 
performance. We therefore aimed to examine the placebo and nocebo effects of a wider range of 
ergogenic aids on sports performance. We hope that the review will provide useful information 
regarding the findings and quality of research. While the term ‘placebo effect’ is often used to 
describe a range of psychologically-mediated factors that influence sport performance (e.g. 
participant-practitioner relationship, white coat syndrome and Hawthorne effects; Hróbjartsson & 
Gøtzsche, 2010), in this review, we aim to examine the magnitude of the placebo and nocebo effect 
elicited by a direct experimental manipulation when compared to a no-treatment control group. 
 
Materials and methods 
This systematic review followed the guidelines provided by the Preferred Reporting Items for 
Systematic Review and Meta-Analyses statement (PRISMA; Moher et al., 2015). 
Types of studies 
Studies that aimed to analyse the placebo and nocebo effect on sports and motor performance were 
considered for inclusion. Both within- and between-participant design studies reported in English 
were considered for inclusion. Conference proceedings, reviews, abstracts, book chapters, 
dissertations and unpublished manuscripts were excluded. 
Types of participants 
Only studies including participants described as “apparently healthy” or “athletes” were included. 
Types of interventions 
Studies were only included if they assessed the effect of a placebo or nocebo ergogenic aid, which 
had no biological or mechanical capacity to directly modify the dependent variable. Ergogenic aids 
were categorised into nutritional (e.g. caffeine) and mechanical (e.g. Transcutaneous nerve 
stimulation [TENS]). 
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Outcome measures 
Studies that did not report at least one direct measure of performance (e.g. power output, speed, or 
time to completion) and those reporting only subjective outcomes (e.g. pain, fatigue, and perceived 
exertion) were excluded. 
 
Experimental controls 
To enable the quantification of the placebo and nocebo effect, only studies that reported either a no-
treatment control, or in repeated measures studies, a baseline in which participants’ own 
performance acted as a no-treatment control, were included. We excluded studies that reported 
experimental or control treatments of questionable rigour, for example when participants’ knowledge 
concerning whether or not they had been given a placebo or the ‘real’ treatment was not measured 
and reported. 
 
Search strategy 
Six electronic databases were searched from their earliest entries up until March 2019 (i.e. Medline, 
Web of Science, PubMed, EBSCO, Science Direct, and Scopus). Reference lists of studies that were 
considered for inclusion and studies citing these articles were examined. The following search 
strategy was applied: “placebo effect” OR “nocebo effect” OR “belief effect” OR “placebo response” 
OR “nocebo response” OR “deceptive” OR “deception” OR “patient expectation” AND “sport” OR 
“performance” OR “motor” OR “exercise.” 
Data collection and analysis 
Abstracts of records identified through electronic databases were read by the lead author, who 
excluded all records that did not meet inclusion criteria. The lead and second author read all other 
records in full and decided on study inclusion independently. Disagreements were resolved by 
discussion with a third author. 
 
Study characteristics were extracted from all eligible reports including author name, year published, 
dependent variable, type of placebo treatment, sample size, type of participant and study design. In 
papers reporting more than one dependent variable, decisions about which one to choose were made 
by the lead, second and last author, with disagreements resolved via discussion.  
 
A thorough assessment of bias was performed by the lead and second author for all eligible studies. 
As recommended by The Cochrane Collaboration (Higgins et al., 2011), each potential risk of bias was 
graded as high, low or unclear. If studies reported random sequence generation (e.g. participants 
randomised to intervention), allocation concealment (e.g. researchers are unaware of which 
treatment participant is in), complete outcome data (e.g. systematic differences between groups in 
withdrawals from a study) and were free of selective reporting (e.g. results that are not significant are 
deliberately left out), the overall risk of bias was considered “low.” All other studies were categorised 
as “unclear” or “high risk” of bias, for example when researchers or participants were aware of which 
treatment was given to the participant. However, given that in placebo effect research a key 
methodological characteristic is that participants are led to believe the treatment they receive will 
influence their performance, we also assessed whether the study measured participants’ belief in the 
effectiveness of the placebo treatment they received through post-study manipulation checks. If a 
manipulation check was included, and study outcomes were discussed in light of this, the study was 
considered as having a low risk of bias.  
Mean and standard deviations of main performance measure were extracted from each study. In 
instances where data were not explicitly reported, the corresponding authors were contacted and 
asked to provide means and standard deviations. We were unable to obtain the data from two studies 
(Clark, Hopkins, Hawley, & Burke, 2000; Tallis, Muhammad, Islam, & Duncan, 2016). For Tallis et al. 
(2016), means and standard errors (SE) were reported in a figure and we estimated the standard 
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deviations by multiplying the SE by the square root of the sample size (Burda, O'Connor, Webber, 
Redmond, & Perdue, 2017). For Clark et al. (2000), means and 95% confidence intervals were 
reported in a figure as percent change from baseline. We were therefore unable to extract means and 
standard deviations of the performance measure and the study was excluded from analysis. 
The mean difference between placebo and controls was standardised by calculating Cohen’s d (d); the 
difference between means of both treatments divided by the pooled standard deviation, using an 
online statistical spreadsheet (Thalheimer & Cook, 2002). For studies that did not include a no-
treatment control, baseline condition was used. Differences between 0.2 and <0.5 were interpreted 
as a small effect, between 0.5 and <0.8 as moderate, and ≥0.8 as large (Cohen, 1992). In addition, 
aggregated effect sizes of studies were calculated to determine potential moderators of the placebo 
effect: 
1. Type of ergogenic aid (i.e. nutritional and mechanical) 
2. Type of placebo (e.g. caffeine, cold-water immersion or kinesiology tape) 
3. Mechanism (i.e. positive expectation, negative expectation or classical conditioning)  
 
Where possible, data are reported as means, standard deviations and 95% CI confidence intervals.  
Results 
Description of studies 
The database search identified 4,026 potential studies, with a further 8 identified through other 
resources (e.g. reference lists of articles). On closer inspection, 3,914 did not specifically measure the 
placebo effect, 74 were duplicate publications and 4 sampled non-healthy participants (e.g. 
participants with ankle instability or Parkinson’s disease). Thus, 42 studies were assessed for eligibility. 
After reading each study in full, three were excluded as they did not meet the inclusion criteria 
regarding control condition (Corsi & Colloca, 2017; Higgins & Shabir, 2016; Reeser et al., 2005), two 
used non-healthy participants (Benedetti et al., 2003; Sawkins, Refshauge, Kilbreath, & Raymond, 
2007), two used placebos that were distinguishable from the experimental treatment (Janes et al., 
2016; Sabino-Carvalho et al., 2017), two did not report the results of the performance outcome 
(Benedetti, Durando, Giudetti, Pampallona, & Vighetti, 2015; Broelz et al., 2019) and one failed to 
deceive participants (Saunders et al., 2010). The final analyses therefore included 32 studies (table 1). 
Figure 1 provides a flow chart of study selection. 
Of these studies, 20 used a between participant design and 12 used a within participant design. Six 
studies used a within-balanced placebo design.1 Twenty investigated placebo effects of nutritional 
ergogenic aids and twelve mechanical (table 2). Five studies aimed to investigate the nocebo effect on 
performance (Andani, Tinazzi, Corsi, & Fiorio, 2015; Beedie, Coleman, & Foad, 2007; Bottoms, 
Buscombe, & Nicholettos, 2014; Hurst et al., 2017; Pollo, Carlino, Vase, & Benedetti, 2012), four 
studies administered a placebo and told participants it was a placebo (Bellinger & Minahan, 2016; 
Duncan, 2010; Duncan, Lyons, & Hankey, 2009; Foad, Beedie, & Coleman, 2008) and five studies used 
a preconditioning procedure in which a placebo is administered after surreptitiously augmenting the 
feedback of a previous performance (Andani et al., 2015; Fiorio, Emadi Andani, Marotta, Classen, & 
Tinazzi, 2014; Pollo, Carlino, & Benedetti, 2008; Pollo et al., 2012). 
Studies were published between 1972 and 2018. Healthy participants were typically included (n = 13), 
with sub-elite athletes (n = 12), university students (n = 6) and elite athletes (n = 1) also sampled. 
                                                             
1 The balanced placebo design uses four conditions; inform no-treatment/receive no-treatment; inform 
treatment/receive no-treatment; inform no-treatment/receive treatment; and inform treatment/receive 
treatment. 
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Sample sizes ranged from 6 to 712 (mean ± SD: 47 ± 123), with the majority of participants being male 
(68.5%). One study included over 100 (n = 712) participants (Hurst et al., 2017), four reported 
between 50 and 100 (range n = 51 to 70) participants (de la Vega, Alberti, Ruiz-Barquin, Soos, & 
Szabo, 2017; Fiorio et al., 2014; Pollo et al., 2012; Villa‐Sánchez, Emadi Andani, & Fiorio, 2018) and 29 
studies were conducted with 50 or fewer (range n = 6 to 42) participants. Overall, there were 1,513 
participants.  
Risk of bias in included studies 
The methodological quality of the studies included in the review was generally poor (figure 2). Four of 
the 32 (12%) trials fulfilled all criteria and were judged as presenting a low risk of bias (Beedie, Stuart, 
Coleman, & Foad, 2006; Duncan, 2010; Saunders et al., 2017; Urroz, Colagiuri, Smith, Yeung, & 
Cheema, 2016). Randomisation to treatment was clearly used in 21 studies (66%) and allocation 
concealment was clear in 8 studies (25%). Eighteen studies (56%) used a manipulation check to 
confirm that the deception of the placebo treatment was successful. Dropouts in included studies 
were rare, with 28 studies reporting no dropouts (87%) and 31 of the 32 studies were free of selective 
reporting (97%). Other types of biases were present in 6 studies (20%). It should be noted that five 
studies (16%) included were conducted by the authors of this review (Beedie et al., 2007; Beedie et 
al., 2006; de la Vega et al., 2017; Foad et al., 2008; Hurst et al., 2017).  
Preliminary and descriptive results 
Nutritional ergogenic aids 
In eight studies the placebo effect of caffeine on performance was investigated (Beedie et al., 2006; 
Duncan, 2010; Duncan et al., 2009; Pires et al., 2018; Pollo et al., 2008; Saunders et al., 2017; Tallis et 
al., 2016). Beedie et al. (2006) reported that the belief that 4.5mg·kg-1 and 9.0mg·kg-1 of caffeine had 
been received improved cycling power output by 1.3% (d = 0.08) and 3.1% (d = 0.21), respectively, 
whereas the belief that a placebo was received impaired performance by -1.4% (d = 0.8). Duncan et 
al. (2009) found that the total weight lifted during a leg extension task was improved by 23.8% (d = 
0.93) when participants received a placebo believed to be caffeine. Pires et al. (2018) reported that 
after the ingestion of a placebo believed to be caffeine, participants’ cycling peak power output 
improved by 10.4% (d = 0.88). Saunders et al. (2017) reported that placebo caffeine improved cycling 
power output by on average 1.0% (d = 0.07). Authors also found that participants’ belief about which 
treatment they received (i.e. “caffeine,” “do not know,” “placebo”) moderated the placebo effect. 
Those that believed they had received a placebo showed impairments in performance of -1.4% (d = 
0.08), whereas those that did not know what they received and those believing they received caffeine 
improved by 2.4% (d = 0.14) and 3.5% (d = 0.27), respectively. Pollo et al. (2008) reported that 
placebo caffeine improved the amount of weight lifted during a leg extension task by 11.4% (d = 
0.29). In the same study, the authors used a deceptive preconditioning procedure, whereby the 
administration of placebo caffeine was coupled with surreptitiously reducing the amount of weight 
lifted, giving participants the impression that the task had become easier with the administration of 
the treatment. In a follow up trial, and with the weight returned to normal, authors reported that 
placebo caffeine improved the total weight lifted by 25.9% (d = 0.82). 
Three studies used a balanced-placebo design to investigate the placebo effect of caffeine on 
performance. Compared to baseline, Foad et al. (2008) reported improvements in power output 
during 40-km cycling time-trials, during the overt (2.3%, d = 0.28) and hidden (2.9%, d = 0.34) 
administration of caffeine. Authors reported no changes in performance when participants received 
placebo believed to be caffeine (0.1%, d = 0.05) but decreases in performance when participants 
received placebo believed to be placebo (-1.9%, d = 0.13). Duncan (2010) reported improvements in 
mean power output during a 30-second Wingate test for the overt (24.5%, d = 1.55) and hidden 
(3.2%, d = 0.20) administration of caffeine. Improvements were also reported when participants 
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received placebo believed to be caffeine (6.5%, d = 0.41). Similarly, Tallis et al. (2016) found that the 
overt administration of caffeine and deceptively hidden administration of placebo (i.e. administering a 
placebo but informing the participant it is caffeine) improved maximal voluntary concentric 
contractile force of the knee extensor muscles by 15.8% (d = 0.60) and 11.2% (d = 0.40), respectively. 
Nevertheless, no significant improvements were reported during the hidden administration of 
caffeine (6.2% d = 0.25).  
Using a within-participant balanced-placebo design, Bellinger and Minahan (2016) reported 
improvements in 1-km cycling power output compared to baseline following consumption of β-
alanine, irrespective of whether it was described as a performance enhancing supplement (2.4%, d = 
0.14) or placebo (1.8%, d = 0.10). Minimal differences in performance were reported when 
participants received a placebo described as β-alanine (0.6%, d = 0.06) or placebo (-1.0%, d = 0.04). 
McClung and Collins (2007) also used a balanced-placebo design to investigate the placebo and true 
effect of sodium bicarbonate on 1000-m running time-trial performance. Authors reported that the 
overt administration of sodium bicarbonate and the expectation of receiving sodium bicarbonate 
improved performance by 1.7% (d = 0.14) and 1.5% (d = 0.13), respectively. However, when 
participants received sodium bicarbonate but expected a placebo, performance decreased by -0.3% 
(d = 0.03).  
In a first study to explicitly investigate the nocebo effect on sports performance, Beedie et al. (2007) 
reported significant decreases in 30-m running speed after the administration of a fictitious 
supplement described as beneficial to endurance but detrimental to speed (-1.7%, d = 0.41). Authors 
also reported significant placebo effects in running speed following the administration of an inert 
capsule described as beneficial. While no change in mean speed was reported compared to baseline 
(0.0%, d = 0.0), the authors suggested that the maintenance of speed over six consecutive trials was 
indicative of a placebo effect when compared to the negative belief group. Similarly, Bottoms et al. 
(2014) investigated both the placebo and nocebo effect on peak minute power during incremental 
arm crank ergometry and found a significant placebo effect on performance (6.3%, d = 0.37), but no 
nocebo effect compared to baseline (-0.8%, d = 0.06). Hurst et al. (2017) investigated the placebo and 
nocebo effect of a fictitious sport supplement on repeat sprint performance with the inclusion of a 
no-treatment control group. Authors found that compared to no treatment controls, performance 
decreased when participants received a placebo that was purported to be harmful to performance (-
0.9%, d = 0.32), but performance did not change when participants received a placebo that was 
purported to be beneficial (-0.1%, d = 0.02).  
In another study investigating placebo effects on sprint performance, de la Vega et al. (2017) reported 
the influence of a fictitious supplement on 200-m sprint performance and randomised participants 
into three groups. Group 1 participants were told the supplement would improve performance, 
Group 2 were told it may or may not improve performance and Group 3 were told it would not affect 
performance. Compared to baseline, sprint times in Group 1 were significantly faster (5.9%, d = 0.28), 
whereas in Group 2 and Group 3, sprint times were similar (Group 2 = 2.2% d = 0.09 and Group 3 = 
1.9%, d = 0.11). Tolusso, Laurent, Fullenkamp, and Tobar (2015) also reported significant 
improvements in participants’ ability to recover from sprinting compared to baseline when runners 
believed they had received a new performance-enhancing substance (5.2%, d = 0.41). 
Kalasountas, Reed, and Fitzpatrick (2007) reported significant improvements in weightlifting 
performance following consumption of a placebo described as amino acids (11.0%, d = 0.36). Hulston 
and Jeukendrup (2009) found no placebo effect during 60-min cycling time-trial after ingestion of 
carbohydrate (0.5%, d = 0.05). Ariel and Saville (1972) and Maganaris, Collins, and Sharp (2000) 
reported significant improvements in weightlifting performance when participants believed they had 
ingested anabolic steroids (9.6%, d = 2.15 and 4.6%, d = 0.72, respectively) and Ross, Gill, Cronin, and 
Malcata (2015) reported significant improvements in 3000-m running time when participants self-
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injected saline, which they believed was a substance similar to recombinant erythropoietin (1.5%, d = 
0.81).  
Mechanical ergogenic aids 
Four studies investigated the placebo effect of transcutaneous electrical nerve stimulation (TENS) on 
performance (Andani et al., 2015; Fiorio et al., 2014; Pollo et al., 2002; Villa‐Sánchez et al., 2018). 
Fiorio et al. (2014) investigated the placebo effect of TENS on peak abduction force produced by the 
right index finger. Performance improved by 14.4% (d = 1.05) when participants believed they had 
received TENS. Similar performance improvements were shown after a preconditioning procedure in 
which the force produced was surreptitiously increased (13.8%, d = 1.11). In a follow up study, and 
using a similar experimental design, Andani et al. (2015) investigated the nocebo effect on force 
production of the right index finger. Compared to no-treatment controls, performance decreased by 
12.9% (d = 0.96) following a preconditioning procedure in which the force produced was 
surreptitiously decreased. Pollo et al. (2012) investigated the nocebo effect of TENS on leg extension 
in two separate experiments. In the first experiment, performance reduced by 11.2% (d = 0.67) when 
participants believed they had received a harmful treatment. In a second experiment, authors 
reported a reduction in performance of 8.5% (d = 0.52) after a preconditioning nocebo-inducing 
procedure. Villa‐Sánchez et al. (2018) also investigated the placebo effect of TENS in two separate 
experiments. In the first experiment, maximal force production of the right index finger improved by 
2.4% (d = 1.22) after participants were administered TENS and informed that it would benefit 
performance. In the second experiment, maximal force improved by 4.3% (d = 0.93) compared to 
baseline after a surreptitious preconditioning procedure. 
In three experiments, Cheung and colleagues investigated the placebo effect of Kinesiology tape on 
peak force of quadriceps (Poon et al., 2015), maximal vertical jump height (Cheung et al., 2016) and 
maximal handgrip strength (Cai, Au, An, & Cheung, 2016). All studies used a similar within-participant 
design and compared Kinesiology tape to placebo and no-treatment control. All studies reported no 
changes in performance for Kinesiology tape compared to controls, (range = 1.46 to 4.68%, d range = 
0.04 to 0.08) or placebo (range = 0.6 to 2.55%, d range = 0.02 to 0.05).  
In two studies, the placebo effect of ischemic preconditioning on swimming performance was 
investigated (Ferreira et al., 2016; Marocolo, da Mota, Pelegrini, & Appell Coriolano, 2015). Marocolo 
et al. (2015) reported improvements in performance after ischemic preconditioning compared to 
baseline (1.5%, d = 0.24) and placebo (0.9%, d = 0.16), whereas Ferreira et al. (2016) reported 
improvements in performance after ischemic preconditioning (1.2%, d = 0.54) but not for placebo 
(0.01%, d = 0.04).  
Guillot, Genevois, Desliens, Saieb, and Rogowski (2012) investigated the placebo effect on tennis 
serve velocity. After baseline trials of fastest tennis serve, participants were given a racket that was 
suggested to enhance serve performance. Compared to baseline, participants’ tennis serve velocity 
improved by 5.65% (d = 0.36). Broatch, Petersen, and Bishop (2014) examined the placebo effect of 
cold-water immersion on maximal voluntary contraction following high-intensity exercise. Compared 
to controls, authors reported a significant improvement in performance when participants received 
cold-water immersion (10.6%, d = 0.39) and placebo (7.2%, d = 0.11).  
Using a within participant balanced-placebo design, Brazier, Sinclair, and Bottoms (2014) investigated 
the placebo effect of magnetic wristbands on 5-m sprint performance. Compared to a control 
treatment in which no wristband was worn, authors reported no differences in any of the three 
treatments: told wristband/given wristband (-0.4%, d = 0.02), told wristband/given placebo (-2.7%, d = 
0.11), and told placebo/given wristband (-7.2%, d = 0.21).  
Primary results 
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Thirty-two studies with 1,513 participants investigated placebo effects on sport performance. Pooled 
effect sizes revealed a small to moderate effect size across all studies (d = 0.37 ± 0.42, 95% CI = 0.25 
to 0.49).  
Moderators of placebo effects 
Type of placebo 
Small to moderate placebo effects were found for nutritional (n = 1099, d = 0.35 ± 0.44, 95% CI = 0.20 
to 0.51), and mechanical (n = 414, d = 0.47 ± 0.42, 95% CI = 0.25 to 0.68) ergogenic aids. Placebo 
effects of purported anabolic steroids had the largest effect on performance (n = 17, d = 1.44 ± 1.01, 
95% CI = 0.03 to 2.84). Placebo effects elicited by an erythropoietin like substance (n = 15, d = 0.81) 
were also found to have a large effect on performance. Moderate to large effect sizes were reported 
for the placebo effect of TENS (n = 113, d = 0.86 ± 0.22, 95% CI = 0.70 to 1.02), while small to 
moderate effect sizes were reported for amino acids (n = 42, d = 0.36), caffeine (n = 149, d = 0.40 ± 
0.28, 95% CI = 0.23 to 0.57) and placebo tennis rackets (n = 22, d = 0.36). The placebo effect of a 
fictitious sport supplement was found to have a small effect on performance (n = 836, d = 0.21 ± 0.17, 
95% CI = 0.10 to 0.31), while null effects were found for cold-water immersion (n = 30, d = 0.18), 
sodium bicarbonate (n = 16, d = 0.13), ischemic preconditioning (n = 38, d = 0.10 ± 0.08, 95 CI = 0.00 
to 0.22), carbohydrate (n = 10; d = 0.05), β-alanine (n = 8, d = 0.06), kinesiology tape (n = 93, d = 0.04 
± 0.02, 95% CI = 0.02 to 0.05) and magnetic wristbands (n = 18, d = 0.11).  
Procedures and participants’ belief 
Preconditioning procedures, whereby a placebo is administered after surreptitiously augmenting the 
perceived performance on a previous performance, was found to have a large effect on performance 
(n = 257, d = 0.82 ± 0.18, 95% CI = 0.66 to 0.97). Small to moderate effect sizes were found for 
positive (n = 985, d = 0.36 ± 0.44, 95% CI = 0.21 to 0.50) and negative (n = 265, d = 0.37 ± 0.25, 95% CI 
= 0.12 to 0.61) expectations and null effects were found when participants received a placebo and 
were told they had received a placebo (n = 48, d = 0.08 ± 0.04, 95% CI = 0.04 to 0.12). 
Discussion 
We found a small to moderate placebo effect on sport performance when combining the results of 32 
studies with a total of 1,513 participants. Equally small to moderate effect sizes were found for 
nutritional (n = 1099, d = 0.35) and mechanical (n = 414, d = 0.47) ergogenic aids. Larger placebo 
effects were found when participants were led to believe they were given banned performance 
enhancing ergogenic aids (anabolic steroids; n = 17, d = 1.44, EPO; n = 15, d = 0.87) and 
Transcutaneous Nerve Stimulation (TENS; n = 113, d = 0.86). Moderate effects were found in studies 
investigating placebo effects of caffeine (n = 149, d = 0.40), amino acids (n = 42, d = 0.36) and 
modified tennis rackets (n = 22, d = 0.36).  
The magnitude of the placebo effect varies depending on the type of placebo and on how the effects 
are induced. Our review illustrates that using pre-conditioning procedures leads to larger placebo 
effects (n = 257, d = 0.82) than studies inducing positive (n = 985, d = 0.36 ± 0.44) and negative (n = 
265, d = 0.37) expectations, a finding consistent with Pollo et al. (2008) who directly compared both 
approaches in a muscle fatigue task. This is consistent with meta-analyses in other research domains 
in which placebo effects induced by expectation have been reported as smaller compared to pre-
conditioning situations (Forsberg, Martinussen, & Flaten, 2017; Petersen et al., 2014; Vase, Riley, & 
Price, 2002).  
The mean effect size reported during overt administration of placebo indicated no effect on 
performance (n = 54, d = 0.08). However, results were mixed between studies, with some reporting 
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significant placebo effects (Duncan, 2010; Duncan et al., 2009) and others reporting significant 
nocebo effects (Foad et al., 2008). Research in other fields has shown that open-label placebos (i.e. 
overt administration of placebo) can significantly improve various conditions such as irritable bowel 
syndrome (Kaptchuk et al., 2010), lower back pain (Carvalho et al., 2016), allergic rhinitis (Schaefer, 
Harke, & Denke, 2016), depression (Kelley, Kaptchuk, Cusin, Lipkin, & Fava, 2012) and cancer related 
fatigue (Hoenemeyer, Kaptchuk, Mehta, & Fontaine, 2018). However, these studies were specifically 
designed to investigate the effects of open-label placebos, whereas studies included in this review 
often use the open-label placebo as a comparator to experimental treatments. Further studies 
directly investigating the effect of open-label placebos on sport performance are needed. 
Strengths and weaknesses of the review  
Two main strengths of our review are the large number of studies examined and the inclusion criteria 
for studies with objective dependent measures (e.g. cycling time-trial performance). This enabled a 
comprehensive assessment of the magnitude of placebo effects on sport performance, provided a 
solid foundation for analyses of the moderators of placebo effects (e.g. type of ergogenic aid), and of 
the risk of bias observed in sport studies.  
Placebo effects are ethically and methodologically problematic to study, and authors are not always 
able to meet standards of methodological rigor than non-deceptive research. For these reasons, the 
methodological quality of studies included in this review was low by stated criteria. Of the 32 studies, 
four (12%) studies scored sufficient for all risk of bias criteria. The most common type of bias was 
allocation concealment, with 69% of studies reported at high risk. Participants in these studies may 
therefore have realised when they received the placebo and subsequently benefited from the 
experimental treatment. While it is appreciated that allocation concealment is practically impossible 
for some treatments (e.g. cold-water immersion and ischemic preconditioning), it is important for 
placebo researchers to ensure manipulation of perceived treatment was effective. However, 41% of 
studies did not satisfy this criterion. Given the poor methodological quality of the studies included in 
this review, the effect size estimates should thus be interpreted with caution.  
The effect sizes presented here could also be underestimated because of the considerable inter-
individual variability in response to the placebo treatment. Given that the proportion of participants 
responding to a placebo treatment varies considerably from study to study, administration of a 
placebo will not always elicit a placebo effect. Placebo effects can be triggered by various factors such 
as the interaction between participant and researcher, the environment in which the treatment is 
delivered, the type of placebo and participants’ previous experiences. Thus, the standard deviation of 
the effect size can be larger than the mean effect. The results from this review, combined with 
previous research from other fields (Benedetti & Amanzio, 2011), underscore the inter-individual 
nature of the placebo effect and highlight the importance of further investigation into potential 
mediators and moderators of its effect on sport performance. Future research should aim to identify 
placebo responders and non-responders in data analyses and further explore the difference between 
groups on treatment outcome.  
Large standard deviations can also be the result of lack of familiarisation to the performance task 
(Hurst & Board, 2017). Generally, performance measures require greater familiarisation before 
reliable data can be obtained (Hopker, Coleman, Wiles, & Galbraith, 2009). The results of this review 
may be limited by the fact that some studies did not familiarise participants to what they were 
required to do and future research should aim to familiarise participants with the performance task 
prior to experimental trials in order to ensure robust and reliable data is collected. 
Implications for research 
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This review has potentially important implications for research in sport science. Findings of studies 
investigating the impact of nutritional and mechanical ergogenic aids on sport performance can be 
susceptible to placebo effects. Researchers should therefore ensure that they are adequately 
controlling for the placebo effect during efficacy trials, in which the performance of a treatment is 
examined under controlled conditions (e.g. randomised controlled trials). To achieve this, researchers 
should use placebos that are indistinguishable from the actual treatment, and control for participants’ 
knowledge or correct guessing of the received treatment. 
Our results also highlight that participants’ prior experiences with a treatment can significantly 
influence the efficacy of that treatment. Participants recruited for a study may have heightened 
expectations and conditioned responses to a treatment, which could influence outcomes. 
Researchers should therefore aim to measure, analyse and report participants’ experiences and 
expectations about a treatment during the experiment to help facilitate an accurate estimation of its 
efficacy. 
Implications for practice 
We found that placebo effects can have a significant impact on sport performance. Given that 
treatment effect sizes larger than d = 0.2 are suggested to be beneficial for athletes (Hopkins, Hawley, 
& Burke, 1999), the average effect size of d = 0.38 reported here suggests that placebo effects can be 
of value for an athlete’s performance. While it has been advocated before that athlete support 
personnel (i.e. coaches, doctors, physiotherapists) should not explicitly use placebos to improve 
performance (Beedie et al., 2017), these results do highlight that if an athlete does not fully believe in 
the effectiveness of a ‘real’ treatment, that athlete may not fully benefit from it. On this basis, it is 
reasonable to suggest that athlete support personnel should endeavour to maximise the placebo 
effect of a legitimate treatment by engendering a positive belief in its effectiveness (c.f. Beedie, Foad, 
& Hurst, 2015) 
Placebo effects were larger for placebos purporting to be ergogenic aids that are banned by 
regulatory bodies in sport (i.e. doping substances). While to date there is no data to support this it 
could be speculated that athletes believing that doping substances are banned for a reason (i.e. they 
have a significant ergogenic effect) this may reinforce the belief that they are effective. It could 
therefore be suggested that banning a substance in sport may have an unintended consequence and 
increase its performance enhancing effectiveness. Given this, if athletes are made aware of the fact 
that a large proportion of the benefit of a performance enhancing drug could be attributed to their 
belief in it rather than the actual pharmacological effect, they may be less likely to consider using it 
(Hurst, Kavussanu, Boardley, & Ring, 2019). National governing bodies and policy organisations aiming 
to reduce drug use should therefore consider educating athletes about the impact the placebo effect 
has on sport performance in anti-doping prevention programmes. 
Conclusion 
The studies reviewed here suggest that placebo effects have a small to moderate effect on sport 
performance. Given that in sport a small effect could influence the outcome on an event, even an 
athletes’ sporting career, the small to moderate sizes reported here could be meaningful. This review 
confirms that various forms of placebos can influence sport performance and that nutritional and 
mechanical ergogenic aids are susceptible to the placebo effect. Larger placebo effects are reported 
for banned performance enhancing substances, such as anabolic steroids and EPO, and when using 
pre-conditioning procedures. Future research is needed that augments our understanding of the 
mediators and moderators of the placebo effect on sport performance. 
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Table 1. Characteristics and findings of placebo effect research on sports performance 
# Authors Year Design Sample 
size 
Type of participant Performance measure Treatment d % change 
Informed Received 
Nutritional and pharmacological ergogenic aids 
1 Ariel et al., 1972 Within-participant 6 University athletes Maximal weight lifted Anabolic steroids Placebo 2.15 9.6 
           
2 Maganaris et 
al., 
2000 Within-participant 11 Elite athletes Maximal weight lifted Anabolic steroids Placebo 0.72 4.6 
           
3 Beedie et al., 2006 Within-participant 6 Sub-elite athletes 10-km TT Placebo Placebo 0.08 -1.4 
4.5mg caffeine Placebo 0.08 1.3 
9.0mg caffeine  Placebo 0.21 3.1 
           
4 Kalasountas et 
al., 
2007 Between-
participant  
42 University athletes Maximal weight lifted Amino acids Placebo 0.36 11 
           
5 McClung et al.,  2007 Within-participant 
balanced placebo 
design 
16 Sub-elite athletes 1000-m TT Sodium 
bicarbonate 
Sodium 
bicarbonate 
0.14 1.7 
Sodium 
bicarbonate 
Placebo 0.13 1.5 
Placebo Sodium 
bicarbonate 
0.03 -0.3 
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Table 1 cont. 
# Authors Year Design Sample size Type of 
participant 
Performance measure Treatment d % 
change 
Informed Received 
6 Beedie et al., 2007 Between-participant  42 Sub-elite 
athletes 
30-m repeated sprints Positive supplement Placebo 0.00 0.0 
Negative 
supplement 
Placebo 0.41 -1.7 
7 Foad et al., 2008 Within-participant 
balanced placebo 
design 
14 Sub-elite 
athletes 
40-km TT Caffeine Caffeine 0.28 2.3 
Caffeine Placebo 0.05 0.1 
Placebo Caffeine 0.34 2.9 
Placebo Placebo 0.13 -1.9 
           
8 Pollo et al., 2008 Between-participant 44 University 
students 
Leg Extension Caffeine Placebo 0.29 11.4 
Caffeine Placebo and 
conditioning 
0.82 25.9 
           
9 Duncan et al., 2009 Within-participant 12 Healthy 
participants 
Leg extension Caffeine Placebo 0.93 23.8 
           
10 Hulston et al.,  2009 Within-participant 10 Sub-elite 
athletes 
60-minute TT 50% change of 
carbohydrate or 
placebo 
Caffeine 1.01 11.0 
Placebo 0.05 0.5 
           
11 Duncan 2010 Within-participant 
balanced placebo 
design 
14 Healthy 
participants 
Wingate Caffeine Caffeine 1.55 24.5 
Caffeine Placebo 0.41 6.5 
Placebo Caffeine 0.20 3.2 
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Table 1 cont. 
# Authors Year Design Sample 
size 
Type of 
participant 
Performance measure Treatment d % 
change 
Informed Received 
12 Bottoms et al., 2014 Within-participant 12 Healthy 
participants 
Arm crank ergometer Positive 
supplement 
Placebo 0.37 6.3 
Negative 
supplement 
Placebo 0.06 -0.8 
           
13 Ross et al., 2015 Within-participant 15 Sub-elite 
athletes 
3000-m TT Oxy RBX Placebo 0.81 1.5 
           
14 Tolusso et al., 2015 Within-participant 10 Healthy 
participants 
Repeated anaerobic sprint test 
(RAST) 
New sport 
supplement 
Placebo 0.41 5.2 
           
15 Bellinger et al., 2016 Within-participant 
balanced placebo 
design 
8 Sub-elite 
athletes 
1kmTT β-alanine β-alanine 0.14 2.4 
β-alanine Placebo 0.06 0.6 
Placebo β-alanine 0.10 1.8 
Placebo Placebo 0.04 -1.0 
           
16 Saunders et al., 2016 Within-participant 42 Sub-elite 
athletes 
25-minute TT Caffeine (guessed 
placebo) 
Placebo -
0.08 
-1.4 
Caffeine (didn't 
know) 
Placebo 0.14 2.4 
Caffeine (guessed 
caffeine) 
Placebo 0.27 3.5 
Caffeine (overall) Placebo 0.07 1.0 
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Table 1 cont. 
# Authors Year Design Sample size Type of 
participant 
Performance measure Treatment d % 
change Informed Received 
17 Tallis et al., 2016 Within-participant 
balanced placebo 
design 
14 Healthy 
participants 
Leg extension Caffeine Caffeine 0.60 15.8 
Caffeine Placebo 0.25 6.2 
Placebo Caffeine 0.40 11.2            
18 de la Vega et 
al., 
2017 Between-participant  60 Healthy 
participants 
200-m sprint Beneficial 
supplement 
Placebo 0.28 5.9 
Partially beneficial 
supplement 
Placebo 0.09 2.2 
Neutral supplement Placebo 0.11 1.9            
19 Hurst et al., 2017 Between-participant  712 Sub-elite 
athletes 
20-m repeated sprints Positive sport 
supplement 
Placebo 0.02 0.10 
Negative sport 
supplement 
Placebo 0.32 -0.9 
           
20 Pires et al., 2018 Within-participant 9 Healthy 
participants 
Cycling maximal incremental test Caffeine Placebo 0.88 10.4 
Mechanical ergogenic aids 
21 Guillot et al., 2012 Between-participant  22 Sub-elite 
athletes 
Tennis Serve Enhanced tennis 
racket 
Placebo 0.36 5.6 
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Table 1 cont. 
# Authors Year Design Sample size Type of 
participant 
Performance measure Treatment d % 
change Informed Received 
22 Pollo et al., 2012 Between-participant 70 Healthy 
participants 
Leg extension Transcutaneous 
electrical nerve 
stimulation 
Placebo 0.67 -11.2 
Transcutaneous 
electrical nerve 
stimulation 
Placebo and 
conditioning 
0.52 -8.5 
           
23 Brazier et al., 2014 Within-participant 
balanced placebo 
design 
18 University 
students 
5-m sprint Magnetic  
wristband 
Magnetic  
wristband 
0.02 0.4 
Magnetic  
wristband 
Placebo 0.11 2.7 
Placebo Magnetic  
wristband 
0.21 7.2 
           
24 Broatch et al., 2014 Between-participant 30 Healthy 
participants 
Leg extension Cold-water 
immersion 
Cold-water 
immersion 
0.39 10.6 
New developed 
recovery oil 
Placebo 0.18 7.3 
           
25 Fiorio et al., 2014 Between-participant 60 University 
students 
Abduction of the right index finger Transcutaneous 
electrical nerve 
stimulation 
Placebo 0.87 14.4 
Transcutaneous 
electrical nerve 
stimulation 
Placebo and 
conditioning 
0.85 13.8 
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# Authors Year Design Sample size Type of 
participant 
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26 Andani et al., 2015 Between-participant 32 Healthy 
participants 
Abduction of the right index finger Transcutaneous 
electrical nerve 
stimulation 
Placebo and 
conditioning 
0.96 -12.9 
           
27 Marocolo et al., 2015 Between-participant 15 Sub-elite 
athletes 
100-m front crawl TT Ischemic 
preconditioning 
Ischemic 
preconditioning 
0.24 1.5 
Placebo Placebo 0.16 0.9 
           
28 Poon et al., 2015 Within-participant 30 Healthy 
participants 
Leg extension Kinesiology tape Kinesiology 
tape 
0.08 2.8 
Kinesiology tape Placebo 0.02 0.6 
           
29 Ferreira et al., 2016 Between-participant 23 University 
athletes 
6 x 50-m sprints Ischemic 
preconditioning 
Ischemic 
preconditioning 
0.54 1.2 
Ischemic 
preconditioning 
Placebo 0.04 0.08 
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# Authors Year Design Sample size Type of 
participant 
Performance measure Treatment d % 
change 
Informed Received 
30 Cai et al., 2016 Within-participant 33 Healthy 
participants 
Handgrip Kinesiology tape Kinesiology 
tape 
0.07 4.7 
Kinesiology tape Placebo 0.04 2.6 
           
31 Cheung et al., 2016 Within-participant 30 Sub-elite 
athletes 
Standing long jump Kinesiology tape Kinesiology 
tape 
0.04 1.0 
Kinesiology tape Placebo 0.05 1.5 
           
32 Villa-Sanchez et 
al. 
2018 Within-participant 51 Healthy 
participants 
Abduction of the right index finger Transcutaneous 
electrical nerve 
stimulation 
Placebo 1.22 2.4 
Transcutaneous 
electrical nerve 
stimulation 
Placebo and 
conditioning 
0.93 4.3 
 
Table 1 caption: Note: d = Cohens d effect statistic, TT = Time-trial 
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Table 2. Types of ergogenic aids investigated in placebo effect studies 
Ergogenic aid Type n = 
Nutritional Caffeine 8 
Fictitious supplement 5 
Anabolic steroids 2 
Amino Acids 1 
B-alanine 1 
Carbohydrate 1 
Erythropoietin 1 
Sodium bicarbonate 1 
Mechanical  Transcutaneous Nerve Stimulation 4 
Kinesiology tape 3 
Ischemic preconditioning  2 
Magnetic wristband 1 
Tennis racket 1 
Cold-water immersion 1 
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Figure captions 
Figure 1. Study flow diagram 
Figure 2. Assessment of bias of all studies. Authors’ judgments about the risk of bias presented as 
percentages across all included studies 
